Related Experiment Video

Updated: Jun 27, 2026

An Ex vivo Culture System to Study Thyroid Development
08:33

An Ex vivo Culture System to Study Thyroid Development

Published on: June 6, 2014

Expression of the ErbA-beta class of thyroid hormone receptors is selectively lost in human colon carcinoma

S Markowitz1, M Haut, T Stellato

  • 1Department of Medicine, Case Western Reserve University, Cleveland, Ohio 44106.

The Journal of Clinical Investigation
|November 1, 1989
PubMed

Insights

Loss of erbA-beta gene expression is linked to colon cancer. This study found reduced erbA-beta transcripts in tumors, suggesting a role in malignant transformation.

Area of Science:

  • Molecular Biology
  • Oncology
  • Gene Expression Regulation

Background:

  • The erbA gene family plays roles in cell differentiation and neoplasia.
  • V-erbA oncogene inhibits erythroid differentiation; related transcripts act as transcriptional regulators, including thyroid hormone receptors.
  • Two human genes, erbA-alpha and erbA-beta, are transcriptionally active.

Purpose of the Study:

  • To investigate the expression patterns of erbA-related transcripts in normal and neoplastic colon tissues.
  • To determine if erbA-beta gene expression is altered during colon cancer development.

Main Methods:

  • Analysis of erbA-related transcript expression in normal colon mucosa, colon polyps, and colon cancer tissues using techniques like Northern blotting (implied).
  • Comparison of transcript levels between cancerous and non-involved adjacent tissues from the same patients.
  • Investigation for gene deletion as a cause for reduced erbA-beta expression.

Main Results:

  • Three characteristic erbA-related transcripts (one erbA-beta related, two erbA-alpha related) were detected in normal colon mucosa, polyps, and polyp cell lines.
  • Expression of the 6 kb erbA-beta transcript was significantly reduced or absent in colon carcinomas compared to non-involved mucosa.
  • Expression levels of erbA-alpha transcripts remained consistent between colon carcinomas and normal mucosa.
  • No evidence of erbA-beta gene deletion was found in tumors with diminished expression.

Conclusions:

  • Selective loss of erbA-beta gene expression is associated with malignant transformation in colonic epithelial cells.
  • The findings suggest a potential role for erbA-beta in the suppression of colon cancer.
  • Further research is warranted to elucidate the specific mechanisms by which erbA-beta loss contributes to colon carcinogenesis.

More Related Videos

Isolation of Human Endothelial Cells from Normal Colon and Colorectal Carcinoma - An Improved Protocol10:54

Isolation of Human Endothelial Cells from Normal Colon and Colorectal Carcinoma - An Improved Protocol

Published on: April 4, 2018

Visualization of Estrogen Receptors in Colons of Mice with TNBS-Induced Crohn's Disease using Immunofluorescence08:02

Visualization of Estrogen Receptors in Colons of Mice with TNBS-Induced Crohn's Disease using Immunofluorescence

Published on: March 12, 2020

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...